Skip to contentB
Bioadaptives, Inc.
B
BDPTBioadaptives, Inc. Q2 2024 · 10-Q
Revenue$675.00$675.00−71.1% vs Q2 2023 Net Income-$183.02K-$183.02KN/M vs Q2 2023 EPS Diluted$0.06$0.06no prior Q2 2023 on file The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioadaptives, Inc. · CIK 1575142 · Engraved from SEC EDGAR
Operating Cash Flowderived-$51,456N/M Margins · derivedGross margin-63.6%−127.3 pt vs Q2 2023
Operating margin-13774.5%−11382.5 pt vs Q2 2023
Net margin-27113.6%−20960.7 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 19, 2024 · 50 d after period end